EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis

P J Gomes, J B Ciolino, P Arranz, G Hernández, N Fernández

Journal of Investigational Allergy and Clinical Immunology · 2024

DOI: 10.18176/jiaci.0894 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Investigational Allergy and Clinical Immunology, 2024. Verfasst von P J Gomes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ora, Inc., Andover, USA. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic, Ophthalmic Solutions, Piperidines, Benzimidazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bilastine is a second-generation antihistamine approved for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. The present trial evaluated the efficacy and safety of a new bilastine 0.6% preservative-free eye drop formulation for the symptomatic treatment of allergic conjunctivitis.

Methods

This phase 3, multicenter, double-masked, randomized study compared the efficacy, safety, and tolerability profile of bilastine 0.6% ophthalmic solution with that of ketotifen 0.025% and vehicle. The primary efficacy endpoint was reduction in ocular itching. The Ora-CAC® Allergen Challenge Model was used to assess ocular and nasal symptoms at 15 minutes (onset of action) and 16 hours after treatment.

Results

Patients (N=228) were 59.6% male, and the mean (SD) age was 44.1 (13.4) years. Bilastine demonstrated efficacy in reducing ocular itching compared to vehicle at both onset of action and 16 hours after treatment (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Conjunctivitis, AllergicOphthalmic SolutionsPiperidinesBenzimidazolesHumansMaleFemaleAdultMiddle AgedDouble-Blind MethodTreatment OutcomePreservatives, PharmaceuticalKetotifenYoung Adult

Stichwörter der Autor:innen

Allergic conjunctivitisAntihistamineBilastineOnce-dailyPreservative-free

Substanzen

Ophthalmic SolutionsbilastinePiperidinesBenzimidazolesPreservatives, PharmaceuticalKetotifen

Autor:innen und Institutionen

  • Ora, Inc., Andover, USA.
  • Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, USA.
  • Department of Research, Development and Innovation, FAES FARMA, Bizkaia, Spain.

Zitieren

APA

Gomes, P. J., Ciolino, J. B., Arranz, P., Hernández, G., & Fernández, N. (2024). Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis. Journal of Investigational Allergy and Clinical Immunology. https://doi.org/10.18176/jiaci.0894

Vancouver

Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis. Journal of Investigational Allergy and Clinical Immunology. 2024. doi:10.18176/jiaci.0894

BibTeX
@article{Gomes2024,
  author = {Gomes, P J and Ciolino, J B and Arranz, P and Hernández, G and Fernández, N},
  title = {Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis},
  journal = {Journal of Investigational Allergy and Clinical Immunology},
  year = {2024},
  doi = {10.18176/jiaci.0894}
}
Kostenlos starten →